# Allianz Biotechnologie
| Asset overview at 31/12/2019 |  |
| --- | --- |
| Breakdown by asset category – country | Market value in EUR | % of net assets  *) |  | Breakdown by asset category – currency | Market value in EUR | % of net assets  *) |
| I. Assets |  |  |  | I. Assets |  |  |
| 1. Equities | 266,674,855.79 | 90.09 |  | 1. Equities | 266,674,855.79 | 90.09 |
| The Netherlands | 5,799,414.37 | 1.96 |  | JPY | 2,252,980.80 | 0.76 |
| Ireland | 10,491,227.17 | 3.54 |  | USD | 264,421,874.99 | 89.33 |
| Denmark | 3,230,629.75 | 1.09 |  | 2. Derivatives | 339,642.13 | 0.11 |
| Switzerland | 705,702.41 | 0.24 |  | 3. Bank deposits, money market | 1,978,916.80 | 0.67 |
| UK | 16,220,616.35 | 5.48 |  | instruments, money market funds and |  |  |
| USA | 223,568,226.35 | 75.53 |  | money market-related funds |  |  |
| Canada | 3,057,704.28 | 1.03 |  | 4. Other assets | 28,588,048.98 | 9.64 |

*) 
Minor rounding differences may be the result of percentage rounding during the calculation.
II. Liabilities	-1,516,977.77	-0.51
| Cayman Islands | 944,981.11 | 0.32 |
| --- | --- | --- |
| British Virgin Islands | 237,951.73 | 0.08 |
| Singapore | 165,421.47 | 0.06 |
| Japan | 2,252,980.80 | 0.76 |
| 2. Derivatives | 339,642.13 | 0.11 |
| 3. Bank deposits, money market instruments, money market funds and | 1,978,916.80 | 0.67 |
| money market-related funds |  |  |
| 4. Other assets | 28,588,048.98 | 9.64 |
| II. Liabilities | -1,516,977.77 | -0.51 |
| III. Fund assets | 296,064,485.93 | 100.00 |

III. Fund assets	296,064,485.93	100.00
Investment portfolio at 31/12/2019
ISIN	Securities	Market	Shares/	Balance   Purchases Redemptions	Price	Market value	% of net
Units/	31/12/2019	EUR	assets
Currency	in the period under review
| Exchange-traded | securities |  |  |  |  |  | 266,674,855.79 | 90.09 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equities |  |  |  |  |  |  | 266,674,855.79 | 90.09 |
| KYG596651029 | MeiraGTx Holdings PLC Reg.Shares | SHS | 28,615 | 28,615 | 0 USD | 20.120 | 514,208.73 | 0.17 |
| US68570P1012 | Orchard Therapeutics PLC Reg.Shs (Sp.ADRs) | SHS | 22,625 | 22,625 | 0 USD | 14.600 | 295,025.23 | 0.10 |
| US88322Q1085 | TG Therapeutics Inc. Reg.Shares | SHS | 43,910 | 43,910 | 0 USD | 10.880 | 426,687.63 | 0.14 |
| Biotechnology |  |  |  |  |  |  | 207,560,442.67 | 70.12 |
| US0042251084 | Acadia Pharmaceuticals Inc. Reg.Shares | SHS | 134,640 | 101,430 | 4,080 USD | 43.970 | 5,287,474.48 | 1.79 |
| US00434H1086 | Acceleron Pharma Inc. Reg.Shares | SHS | 21,495 | 21,495 | 0 USD | 51.130 | 981,591.88 | 0.33 |
| US00773U1088 | Adverum Biotechnologies Inc. Reg.Shares | SHS | 150,160 | 150,160 | 0 USD | 11.210 | 1,503,410.53 | 0.51 |
| US00847X1046 | Agios Pharmaceuticals Inc. Reg.Shares | SHS | 46,740 | 50,645 | 36,045 USD | 48.480 | 2,023,806.73 | 0.68 |
| US00972D1054 | Akebia Therapeutics Inc. Reg.Shares | SHS | 39,220 | 39,220 | 0 USD | 6.520 | 228,387.80 | 0.08 |
| US0144421072 | Alector Inc. Reg.Shares | SHS | 29,355 | 29,355 | 0 USD | 17.600 | 461,437.06 | 0.16 |
| US0153511094 | Alexion Pharmaceuticals Inc. Reg.Shares | SHS | 91,600 | 55,730 | 44,480 USD | 108.550 | 8,880,614.48 | 3.00 |
| US01671P1003 | Allakos Inc. Reg.Shares | SHS | 8,945 | 20,810 | 11,865 USD | 97.690 | 780,455.54 | 0.26 |
| US02043Q1076 | Alnylam Pharmaceuticals Inc Reg.Shares | SHS | 40,060 | 15,800 | 67,645 USD | 117.540 | 4,205,468.14 | 1.42 |
| US0231112063 | Amarin Corp. PLC Reg.Shs (Sp.ADRs) | SHS | 127,283 | 92,710 | 76,860 USD | 21.550 | 2,449,826.87 | 0.83 |
| US0311621009 | Amgen Inc. Reg.Shares | SHS | 112,605 | 49,470 | 57,405 USD | 241.530 | 24,291,060.29 | 8.20 |
| US03152W1099 | Amicus Therapeutics Inc. Reg.Shares | SHS | 42,055 | 42,055 | 0 USD | 9.740 | 365,842.63 | 0.12 |
| US0327241065 | Anaptysbio Inc. Reg.Shares | SHS | 9,685 | 12,090 | 10,350 USD | 16.760 | 144,974.41 | 0.05 |
| US03753U1060 | Apellis Pharmaceuticals Inc. Reg.Shares | SHS | 19,235 | 24,405 | 5,170 USD | 28.740 | 493,738.13 | 0.17 |
| US0400476075 | Arena Pharmaceuticals Inc. Reg.Shares New | SHS | 55,985 | 30,790 | 5,730 USD | 46.050 | 2,302,602.82 | 0.78 |
| US04016X1019 | argenx SE Reg.Shares (Sp.ADRs) | SHS | 15,690 | 12,820 | 4,185 USD | 160.800 | 2,253,339.88 | 0.76 |
| US04280A1007 | Arrowhead Pharmaceuticals Inc. Reg.Shares | SHS | 22,745 | 27,495 | 4,750 USD | 64.930 | 1,319,012.95 | 0.45 |
| US04351P1012 | Ascendis Pharma A/S Nav.-Akt. (Spons.ADRs) | SHS | 26,780 | 19,055 | 17,095 USD | 135.070 | 3,230,629.75 | 1.09 |
| US0453961080 | Assembly Biosciences Inc. Reg.Shares | SHS | 45,005 | 45,005 | 0 USD | 20.935 | 841,494.82 | 0.28 |
| CA05156V1022 | Aurinia Pharmaceuticals Inc. Reg.Shares | SHS | 159,830 | 159,830 | 0 USD | 21.420 | 3,057,704.28 | 1.03 |
| US07725L1026 | BeiGene Ltd. Reg.Shares (Sp.ADRs) | SHS | 2,885 | 13,570 | 46,510 USD | 167.180 | 430,772.38 | 0.15 |
| US09062X1037 | Biogen Inc. Reg.Shares | SHS | 58,625 | 37,155 | 48,390 USD | 300.090 | 15,712,746.17 | 5.31 |
| VGG111961055 | Biohaven Pharmac.Hldg Co.Ltd. Reg.Shares | SHS | 4,755 | 9,525 | 4,770 USD | 56.030 | 237,951.73 | 0.08 |
| US09061G1013 | Biomarin Pharmaceutical Inc. Reg.Shares | SHS | 92,735 | 19,695 | 48,920 USD | 85.590 | 7,088,990.89 | 2.39 |
| US09609G1004 | Bluebird Bio Inc. Reg.Shares | SHS | 11,155 | 21,005 | 46,760 USD | 88.400 | 880,723.44 | 0.30 |
| US09627Y1091 | Blueprint Medicines Corp. Reg.Shares | SHS | 17,715 | 7,785 | 6,460 USD | 81.270 | 1,285,846.51 | 0.43 |
| US10806X1028 | BridgeBio Pharma Inc. Reg.Shares | SHS | 60,750 | 60,750 | 0 USD | 36.840 | 1,998,865.72 | 0.68 |
| US16383L1061 | ChemoCentryx Inc. Reg.Shares | SHS | 60,780 | 60,780 | 0 USD | 36.230 | 1,966,739.07 | 0.66 |
| CH0334081137 | CRISPR Therapeutics AG Nam.-Aktien | SHS | 11,970 | 13,345 | 34,445 USD | 66.010 | 705,702.41 | 0.24 |
| US23284F1057 | Cytomx Therapeutics Inc. Reg.Shares | SHS | 36,745 | 84,040 | 164,760 USD | 8.540 | 280,268.21 | 0.09 |
| US24344T1016 | Deciphera Pharmaceuticals Inc. Reg.Shares | SHS | 34,310 | 44,600 | 10,290 USD | 64.490 | 1,976,199.62 | 0.67 |
| US24823R1059 | Denali Therapeutics Inc. Reg.Shares | SHS | 18,120 | 9,605 | 55,430 USD | 18.280 | 295,836.73 | 0.10 |
| US2530311081 | Dicerna Pharmaceuticals Inc. Reg.Shares | SHS | 67,735 | 140,100 | 72,365 USD | 22.260 | 1,346,653.95 | 0.45 |
| US28249H1041 | Eidos Therapeutics Inc. Reg.Shares | SHS | 13,560 | 54,145 | 40,585 USD | 58.610 | 709,821.46 | 0.24 |
| US29428V1044 | Epizyme Inc. Reg.Shares | SHS | 90,370 | 90,370 | 0 USD | 22.620 | 1,825,721.79 | 0.62 |
| US29664W1053 | Esperion Therapeutic.Inc.(New) Reg.Shares | SHS | 24,850 | 33,145 | 36,230 USD | 59.560 | 1,321,900.59 | 0.45 |
| US30063P1057 | Exact Sciences Corp. Reg.Shares | SHS | 20,840 | 24,580 | 20,395 USD | 94.100 | 1,751,479.48 | 0.59 |
| US30161Q1040 | Exelixis Inc. Reg.Shares | SHS | 37,530 | 45,855 | 76,835 USD | 18.130 | 607,706.78 | 0.21 |
| US31572Q8087 | FibroGen Inc. Reg.Shares | SHS | 16,745 | 38,925 | 31,990 USD | 44.890 | 671,355.38 | 0.23 |
| US34983P1049 | Forty Seven Inc. Reg.Shares | SHS | 74,360 | 74,360 | 0 USD | 44.050 | 2,925,519.58 | 0.99 |
| US3621LQ1099 | G1 Therapeutics Inc. Reg.Shares | SHS | 13,835 | 14,640 | 13,555 USD | 27.570 | 340,669.81 | 0.12 |
| US3755581036 | Gilead Sciences Inc. Reg.Shares | SHS | 304,320 | 148,605 | 171,985 USD | 65.950 | 17,925,158.75 | 6.05 |
| US37890U1088 | Global Blood Therapeutics Inc. Reg.Shares | SHS | 15,510 | 27,535 | 30,470 USD | 79.150 | 1,096,428.79 | 0.37 |
| US40637H1095 | Halozyme Therapeutics Inc. Reg.Shares | SHS | 105,030 | 196,565 | 91,535 USD | 17.980 | 1,686,633.68 | 0.57 |
| US4277461020 | Heron Therapeutics Inc. Reg.Shares | SHS | 29,665 | 22,330 | 156,950 USD | 24.100 | 638,526.77 | 0.22 |
| US4380831077 | Homology Medicines Inc. Reg.Shares | SHS | 36,290 | 36,290 | 0 USD | 21.590 | 699,773.23 | 0.24 |
| US4529071080 | Immunomedics Inc. Reg.Shares | SHS | 70,245 | 31,950 | 41,555 USD | 21.770 | 1,365,814.00 | 0.46 |
| US45337C1027 | Incyte Corp. Reg.Shares | SHS | 63,515 | 38,400 | 73,965 USD | 88.390 | 5,014,148.04 | 1.69 |
| US4576693075 | Insmed Inc. Reg.Shares | SHS | 36,040 | 81,280 | 137,015 USD | 23.740 | 764,158.09 | 0.26 |
| US45845P1084 | Intercept Pharmaceuticals Inc. Reg.Shares | SHS | 11,295 | 11,080 | 4,785 USD | 123.070 | 1,241,526.95 | 0.42 |
| US4622601007 | Iovance Biotherapeutics Inc. Reg.Shares | SHS | 121,685 | 155,785 | 237,260 USD | 27.820 | 3,023,513.33 | 1.02 |
| US48576U1060 | Karyopharm Therapeutics Inc. Reg.Shares | SHS | 24,040 | 37,445 | 13,405 USD | 19.250 | 413,316.66 | 0.14 |
| US4945771099 | Kindred Biosciences Inc. Reg.Shares | SHS | 51,310 | 94,780 | 43,470 USD | 8.450 | 387,236.64 | 0.13 |
| US5011471027 | Krystal Biotech Inc. Reg.Shares | SHS | 9,880 | 34,725 | 24,845 USD | 60.150 | 530,774.80 | 0.18 |
| US60468T1051 | Mirati Therapeutics Inc. Reg.Shares | SHS | 29,355 | 53,060 | 23,705 USD | 128.430 | 3,367,179.61 | 1.14 |
| US60877T1007 | Momenta Pharmaceuticals Inc. Reg.Shares | SHS | 105,570 | 105,570 | 0 USD | 20.360 | 1,919,711.70 | 0.65 |
| US6323071042 | Natera Inc. Reg.Shares | SHS | 13,725 | 13,725 | 0 USD | 33.650 | 412,491.63 | 0.14 |
| US64125C1099 | Neurocrine Biosciences Inc. Reg.Shares | SHS | 36,790 | 18,045 | 52,430 USD | 108.440 | 3,563,173.85 | 1.20 |
| US74257L1089 | Principia Biopharma Inc. Reg.Conv.Shares | SHS | 24,725 | 24,725 | 0 USD | 59.700 | 1,318,342.79 | 0.45 |
| NL0010872495 | ProQR Therapeutics N.V. Aandelen op naam | SHS | 91,070 | 68,080 | 2,820 USD | 9.410 | 765,389.81 | 0.26 |

Investment portfolio at 31/12/2019
ISIN	Securities	Market	Shares/	Balance   Purchases Redemptions	Price	Market value	% of net
Units/	31/12/2019	EUR	assets
Currency	in the period under review
| US74366E1029 | Protagonist Therapeutics Inc. Reg.Shares | SHS | 54,350 | 91,295 | 36,945 USD | 7.000 | 339,793.69 | 0.11 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| US69366J2006 | PTC Therapeutics Inc. Reg.Shares | SHS | 53,025 | 37,310 | 3,585 USD | 48.810 | 2,311,570.80 | 0.78 |
| US75886F1075 | Regeneron Pharmaceuticals Inc. Reg.Shares | SHS | 26,365 | 19,900 | 21,025 USD | 373.320 | 8,790,766.58 | 2.97 |
| US75901B1070 | Regenxbio Inc. Reg.Shares | SHS | 14,555 | 21,515 | 18,885 USD | 40.540 | 527,003.71 | 0.18 |
| US77313F1066 | Rocket Pharmaceuticals Inc. Reg.Shares | SHS | 19,610 | 75,155 | 55,545 USD | 24.060 | 421,396.51 | 0.14 |
| US78667J1088 | Sage Therapeutics Inc. Reg.Shares | SHS | 12,825 | 27,030 | 31,140 USD | 73.350 | 840,185.55 | 0.28 |
| US8006771062 | Sangamo Therapeutics Inc. Reg.Shares | SHS | 112,980 | 66,540 | 76,435 USD | 8.360 | 843,578.62 | 0.28 |
| US8036071004 | Sarepta Therapeutics Inc. Reg.Shares | SHS | 34,135 | 16,680 | 21,855 USD | 129.770 | 3,956,324.70 | 1.34 |
| US8125781026 | Seattle Genetics Inc. Reg.Shares | SHS | 65,610 | 51,530 | 41,980 USD | 113.420 | 6,646,261.06 | 2.24 |
| US90041T1088 | Turning Point Therap. Inc. Reg.Shares | SHS | 41,440 | 50,695 | 9,255 USD | 60.630 | 2,244,011.25 | 0.76 |
| NL0010696654 | uniQure N.V. Aandelen op naam | SHS | 39,780 | 42,635 | 2,855 USD | 72.500 | 2,575,849.60 | 0.87 |
| US92532F1003 | Vertex Pharmaceuticals Inc. Reg.Shares | SHS | 113,835 | 48,735 | 24,180 USD | 220.970 | 22,466,056.31 | 7.59 |
| Biosciences: materials and services |  |  |  |  |  | 12,662,129.10 | 4.28 |
| US4523271090	Illumina Inc. Reg.Shares | SHS | 42,665 | 38,255 | 48,710 USD | 332.290 | 12,662,129.10 | 4.28 |
| Healthcare: equipment and products |  |  |  |  |  | 7,698,497.14 | 2.60 |
| US08862L1035	Beyond Air Inc. Reg.Shares | SHS | 394,056 | 394,056 | 0 USD | 4.380 | 1,541,522.15 | 0.52 |
| JE00BYSS4X48	Novocure Ltd. Reg.Shares | SHS | 58,705 | 14,585 | 32,830 USD | 87.560 | 4,590,907.69 | 1.55 |
| JE00BLG2ZQ72	Quotient Ltd. Reg.Shares | SHS | 192,475 | 43,065 | 121,645 USD | 9.110 | 1,566,067.30 | 0.53 |
| Healthcare: Institutions & Services |  |  |  |  |  | 1,004,437.73 | 0.34 |
| US40131M1099	Guardant Health Inc. Reg.Shares Cl.A | SHS | 14,270 | 14,270 | 0 USD | 78.810 | 1,004,437.73 | 0.34 |
| Pharmaceuticals |  |  |  |  |  | 36,513,427.56 | 12.34 |
| US00771V1089	Aerie Pharmaceuticals Inc. Reg.Shares | SHS | 30,430 | 5,060 | 3,110 USD | 24.020 | 652,818.83 | 0.22 |
| US0463531089	Astrazeneca PLC Reg.Shares (Spons.ADRs) | SHS | 162,460 | 177,205 | 106,995 USD | 50.440 | 7,318,789.26 | 2.47 |
| US1101221083	Bristol-Myers Squibb Co. Reg.Shares | SHS | 140,870 | 207,715 | 66,845 USD | 64.140 | 8,069,844.86 | 2.73 |
| JP3475350009	Daiichi Sankyo Co. Ltd. Reg.Shares | SHS | 38,100 | 38,100 | 0 JPY | 7,228.000 | 2,252,980.80 | 0.76 |
| US24983L1044	Dermira Inc. Reg.Shares | SHS | 172,745 | 236,070 | 63,325 USD | 14.550 | 2,244,844.15 | 0.76 |
| IE00BQPVQZ61	Horizon Therapeutics PLC Reg.Shares | SHS | 323,150 | 420,100 | 96,950 USD | 36.350 | 10,491,227.17 | 3.54 |
| US46116X1019	Intra-Cellular Therapies Inc. Reg.Shares | SHS | 21,835 | 49,880 | 28,045 USD | 35.225 | 686,944.92 | 0.23 |
| NL0011031208	Mylan N.V. Aandelen aan toonder | SHS | 11,630 | 246,960 | 447,445 USD | 19.720 | 204,835.08 | 0.07 |
| US62857M1053	Myokardia Inc. Reg.Shares | SHS | 6,105 | 15,415 | 32,715 USD | 74.120 | 404,146.47 | 0.14 |
| US6402681083	Nektar Therapeutics Reg.Shares | SHS | 38,555 | 40,710 | 19,895 USD | 21.570 | 742,760.10 | 0.25 |
| US6760791060	Odonate Therapeutics Inc. Reg.Shares | SHS | 23,430 | 1,230 | 85,400 USD | 29.520 | 617,740.90 | 0.21 |
| US75615P1030	Reata Pharmaceuticals Inc. Reg.Shares | SHS | 14,100 | 14,100 | 0 USD | 211.310 | 2,661,073.55 | 0.90 |
| SG9999014716	Wave Life Sciences Ltd. Reg.Shares | SHS | 11,715 | 3,865 | 18,920 USD | 15.810 | 165,421.47 | 0.06 |
| Total securities |  |  |  | EUR |  | 266,674,855.79 | 90.09 |
| Derivatives |  |  |  |  |  |  |  |
| (The positions marked with a minus sign have been sold) |  |  |  |  |  |  |  |
| Derivatives on individual securities |  |  |  |  |  |  |  |
| Warrants |  |  |  |  |  | 339,642.13 | 0.11 |
| Equity warrants |  |  |  |  |  | 339,642.13 | 0.11 |
| Advanced Inhalation WTS |  |  |  |  |  |  |  |
| (Foreign) 16/29.12.21	X Advanced Inhalation WTS | SHS | 333,334 | 0 | 0 USD | 0.739 | 220,009.67 | 0.07 |
| (Foreign) 18/01.02.21	X OncoGenex Pharmac. WTS | SHS | 227,389 | 0 | 0 USD | 0.589 | 119,619.63 | 0.04 |
| (Foreign) 04/02.07.19	A | SHS | 143,678 | 0 | 0 USD | 0.0001 | 12.83 | 0.00 |
| Total derivatives on individual securities | EUR |  | 339,642.13 | 0.11 |
| Bank deposits, money market instruments, money market funds and money market-related funds |  |  |  |  |
| Deposits in non EU/EEA currencies |  |  |  |  |
| State Street Bank International GmbH	USD	2,215,694.20 | % | 100.000 | 1,978,916.80 | 0.67 |
| Total bank deposits | EUR |  | 1,978,916.80 | 0.67 |
| Total bank deposits, money market instruments, money market funds and money market-related funds 30) | EUR |  | 1,978,916.80 | 0.67 |
| Other assets |  |  |  |  |
| Receivables from unit transactions	EUR	 27,368,330.76 |  |  | 27,368,330.76 | 9.23 |
| Receivables from securities transactions	EUR	1,219,718.22 |  |  | 1,219,718.22 | 0.41 |
| Total other assets | EUR |  | 28,588,048.98 | 9.64 |
| Short-term liabilities |  |  |  |  |
| EUR loans held with the depository |  |  |  |  |
| State Street Bank International GmbH	EUR	-243,774.22 |  |  | -243,774.22 | -0.08 |
| Total short-term liabilities | EUR |  | -243,774.22 | -0.08 |
| Other payables |  |  |  |  |
| Liabilities from unit transactions	EUR	-271,440.42 |  |  | -271,440.42 | -0.09 |
| Liabilities from securities transactions	EUR	-540,587.45 |  |  | -540,587.45 | -0.18 |
| Accruals	EUR	-461,175.68 |  |  | -461,175.68 | -0.16 |
| Total other payables | EUR |  | -1,273,203.55 | -0.43 |

Investment portfolio at 31/12/2019
ISIN	Securities	Market	Shares/	Balance   Purchases Redemptions	Price	Market value	% of net
Units/	31/12/2019	EUR	assets
Currency	in the period under review
Fund assets	EUR	296,064,485.93	100.00
Total units in circulation of all unit classes	STK	1,692,970
Allianz Biotechnologie A (EUR)
| ISIN | DE0008481862 |
| --- | --- |
| Fund assets | 295,987,458.38 |
| Units in circulation | 1,692,357.701 |
| Unit value | 174.90 |

Allianz Biotechnologie R (EUR)
| ISIN | DE000A2AMPU5 |
| --- | --- |
| Fund assets | 77,027.55 |
| Units in circulation | 612.480 |
| Unit value | 125.76 |

Securities prices/market rates
Fund assets were valued on the basis of the following prices/market rates:
North and South American equities: prices as at 27/12/2019 or last known All other assets: prices/market rates as at 30/12/2019 or last known
Exchange rate(s) and/or conversion factor(s) (indirect quotation) as at 30/12/2019
| USA, Dollar | (USD) | 1 Euro = USD | 1.11965 |
| --- | --- | --- | --- |
| Japan, Yen | (JPY) | 1 Euro = JPY | 122.23220 |
| Market key |  |  |  |
| Securities trading |  |  |  |
| A | = | Official stock market trading |
| X | = | Unlisted securities |
| Capital measures |  |  |

All sales resulting from capital measures (technical sales) are reported as inflows or outflows.
Voting
To the extent that it was deemed necessary in the interests of our investors, we have either exercised voting rights from the shares in the fund ourselves or have them exercised by agents in accordance with our instructions.
Transactions carried out during the reporting period no longer listed in the investment portfolio:
– purchases and redemptions of securities, fund units and borrower’s note loans (market allocations as per reporting date):
ISIN	Securities	Shares/	Purchases	Redemptions Units/
Currency
Exchange-traded securities Equities
| Biotechnology |  |
| --- | --- |
| US00287Y1091 | AbbVie Inc. Reg.Shares | SHS | 26,660 | 26,660 |
| IE00B56GVS15 | Alkermes PLC Reg.Shares | SHS | 0 | 28,085 |
| US04269E1073 | ArQule Inc. Reg.Shares | SHS | 173,345 | 173,345 |
| US05070R1041 | Audentes Therapeutics Inc. Reg.Shares | SHS | 2,885 | 19,145 |
| US05280R1005 | Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs) | SHS | 17,295 | 32,105 |
| US09058V1035 | BioCryst Pharmaceuticals Inc. Reg.Shares | SHS | 46,480 | 46,480 |
| US1510201049 | Celgene Corp. Reg.Shares | SHS | 76,690 | 254,960 |
| US1894641000 | Clovis Oncology Inc. Reg.Shares | SHS | 23,550 | 23,550 |
| US28106W1036 | Editas Medicine Inc. Reg.Shares | SHS | 7,085 | 49,780 |
| US38000Q1022 | GlycoMimetics Inc. Reg.Shares | SHS | 76,965 | 76,965 |
| US45253H1014 | ImmunoGen Inc. Reg.Shares | SHS | 61,655 | 61,655 |
| US45826J1051 | Intellia Therapeutics Inc. Reg.Shares | SHS | 1,990 | 18,365 |
| US46185L1035 | Invitae Corp. Reg.Shares | SHS | 27,850 | 154,125 |
| US4622221004 | Ionis Pharmaceuticals Inc. Reg.Shares | SHS | 2,920 | 38,800 |
| US5560991094 | MacroGenics Inc. Reg.Shares | SHS | 28,000 | 28,000 |
| US62855J1043 | Myriad Genetics Inc. Reg.Shares | SHS | 27,705 | 27,705 |
| US7370101088 | Portola Pharmaceuticals Inc. Reg.Shares | SHS | 26,915 | 26,915 |
| US74373B1098 | Proteostasis Therapeutics Inc. Reg.Shares | SHS | 7,220 | 66,645 |
| US7504692077 | Radius Health Inc. Reg.Shares | SHS | 5,715 | 52,770 |
| US7612991064 | Retrophin Inc. Reg.Shares | SHS | 29,810 | 45,350 |
| US84763A1088 | Spectrum Pharmaceuticals Inc. Reg.Shares New | SHS | 44,385 | 44,385 |
| US5846881051 | The Medicines Co. Reg.Shares | SHS | 86,965 | 113,335 |
| US90400D1081 | Ultragenyx Pharmaceutical Inc. Reg.Shares | SHS | 2,145 | 19,800 |
| US91307C1027 | United Therapeutics Corp.(Del.) Reg.Shares | SHS | 5,655 | 5,655 |
| Biosciences: materials and services |
| US00650F1093 | Adaptive Biotechnologies Corp. Reg.Shares | SHS | 50,000 | 50,000 |
| US09073M1045 | Bio-Techne Corp. Reg.Shares | SHS | 1,670 | 15,443 |
| US63009R1095 | NanoString Technologies Inc. Reg.Shares | SHS | 14,000 | 14,000 |
| US69354M1080 | PRA Health Sciences Inc. Reg.Shares | SHS | 3,035 | 28,035 |
| US87166B1026 | Syneos Health Inc. Reg.Shares A | SHS | 17,615 | 17,615 |
| Healthcare: equipment and products |
| US0014481099 | AIT Therapeutics Inc. Reg.Shares | SHS | 0 | 394,056 |
| Pharmaceuticals |  |  |  |  |
| US1407551092 | Cara Therapeutics Inc. Reg.Shares | SHS | 30,870 | 44,730 |
| US23257D1037 | CymaBay Therapeutics Inc. Reg.Shares | SHS | 24,000 | 24,000 |
| US28414H1032 | Elanco Animal Health Inc. Reg.Shares | SHS | 9,494.691 | 9,494.691 |
| US36197T1034 | GW Pharmaceuticals PLC Reg.Shs (Sp.ADRs) | SHS | 690 | 6,380 |

Securities admitted to or included in regulated markets Equities
Biotechnology
| US04269X1054 | Array Biopharma Inc. Reg.Shares | SHS | 9,375 | 86,530 |
| --- | --- | --- | --- | --- |
| US84652J1034 | Spark Therapeutics Inc. Reg.Shares | SHS | 18,930 | 48,030 |
| Pharmaceuticals US03874P1012 | Aratana Therapeutics Inc. Reg.Shares | SHS | 70,000 | 70,000 |
| Unlisted securities Equities Biotechnology US0143391052 | Alder BioPharmaceuticals Inc. Reg.Shares | SHS | 3,450 | 31,860 |
|  |  |  |  |  |
|  | Securities | Shares/ |  | Volume |
|  |  | Units/ |  | in ’000 |
|  |  | Currency |  |  |
| Derivatives |  |  |  |  |

(Option premiums and/or contract volumes pertaining to opening transactions; in the case of warrants, purchases and redemptions are indicated.)
Forward exchange deals
Foreign exchange futures (purchase) Forward sale of currencies:
| Securities | Shares/ | Volume |
| --- | --- | --- |
|  | Units/ Currency | in ’000 |
| USD/EUR | EUR | 577 |

Transactions carried out during the period under review no longer listed in the investment portfolio: Purchases and redemptions in securities, fund units and notes (market allocations as per reporting date):
| Statement of Operations Unit class: Allianz Biotechnologie A | (EUR) |  |  | Unit class: Allianz Biotechnologie R (EUR) |  |
| --- | --- | --- | --- | --- | --- |
| For the period from 01/01/2019 - 31/12/2019 |  |  |  | For the period from 01/01/2019 - 31/12/2019 |
| (including income equalisation) |  |  |  | (including income equalisation) |
|  | EUR | EUR |  |  | EUR | EUR |
| I. Income |  |  |  | I. Income |  |  |
| 1. Dividends from German issuers (before |  |  |  | 1. Dividends from German issuers (before |  |  |
| corporate income tax) |  | 0.00 |  | corporate income tax) |  | 0.00 |
| 2. Dividends from foreign issuers (gross of |  |  |  | 2. Dividends from foreign issuers (gross of |  |  |
| withholding tax) |  | 1,789,128.49 |  | withholding tax) |  | 462.70 |
| 3. Interest from German securities |  | 0.00 |  | 3. Interest from German securities |  | 0.00 |
| 4. Interest from foreign securities (gross of |  |  |  | 4. Interest from foreign securities (gross of |  |  |
| withholding tax) |  | 0.00 |  | withholding tax) |  | 0.00 |
| 5. Interest from liquid investments in Germany |  | -12,870.37 |  | 5. Interest from liquid investments in Germany |  | -2.94 |
| a) Negative interest on deposits | -13,476.18 |  |  | a) Negative interest on deposits | -2.94 |  |
| b) Positive interest on deposits | 605.81 |  |  | 6. Interest from liquid investments abroad (gross |  |  |
| 6. Interest from liquid investments abroad (gross |  |  |  | of withholding tax) |  | 0.00 |
| of withholding tax) |  | 0.00 |  | 7. Income from fund units |  | 0.00 |
| 7. Income from fund units |  | 0.00 |  | 8. Income from securities loans and repo |  |  |
| 8. Income from securities loans and repo |  |  |  | transactions |  | 0.00 |
| transactions |  | 0.00 |  | 9a. Deduction of domestic corporate income tax |  | 0.00 |
| 9a. Deduction of domestic corporate income tax |  | 0.00 |  | 9b. Deduction of foreign withholding tax |  | -124.93 |
| 9b. Deduction of foreign withholding tax |  | -477,893.64 |  | a) from dividends from domestic issuers | -124.93 |  |
| a) from dividends from domestic issuers | -477,893.64 |  |  | 10. Other income |  | 133.78 |
| 10. Other income |  | 517,264.66 |  | Total income |  | 468.61 |
| Total income |  | 1,815,629.14 |  | II. Expenses |  |  |
| II. Expenses |  |  |  | 1. Interest from loans |  | -0.59 |
| 1. Interest from loans |  | -5,722.90 |  | 2. All-in fee 1) |  | -795.47 |
| 2. All-in fee 1) |  | -5,334,203.15 |  | 3. Depositary fee |  | 0.00 |
| 3. Depositary fee |  | 0.00 |  | 4. Auditing and publication costs |  | 0.00 |
| 4. Auditing and publication costs |  | 0.00 |  | 5. Other expenses |  | -0.44 |
| 5. Other expenses |  | -4,096.83 |  | Total expenses |  | -796.50 |
| Total expenses |  | -5,344,022.88 |  | III. Ordinary net income |  | -327.89 |
| III. Ordinary net income IV. Sales transactions |  | -3,528,393.74 |  | IV. Sales transactions 1. Realised gains |  | 9,879.41 |
| 1. Realised gains |  | 38,121,590.72 |  | 2. Realised losses |  | -6,513.70 |
| 2. Realised losses |  | -25,141,288.20 |  | Result from sales transactions |  | 3,365.71 |
| Result from sales transactions |  | 12,980,302.52 |  | V. Realised result for the financial year |  | 3,037.82 |
| V. Realised result for the financial year |  | 9,451,908.78 |  | 1. Net change in unrealised gains |  | -89.48 |
| 1. Net change in unrealised gains |  | 27,796,516.50 |  | 2. Net change in unrealised losses |  | 432.19 |
| 2. Net change in unrealised losses |  | 28,003,838.63 |  | VI. Unrealised result for the financial year |  | 342.71 |
| VI. Unrealised result for the financial year |  | 55,800,355.13 |  | VII. Result for the financial year |  | 3,380.53 |

VII. Result for the financial year	65,252,263.91
1) 
Under the Terms and Conditions, an all-in fee of up to 2.05% p.a. (in the financial year 2.05% p.a.) is payable to the investment management company on behalf of the fund. The expenses met by the investment management company from this fee included the expenses for portfolio management and the custodian charges (in the financial year 0.008% p.a.) as well as other third party payments (e.g. printing and publication expenses, audit fees, etc.).
1) 
Under the Terms and Conditions, an all-in fee of up to 2.05% p.a. (in the financial year 1.18% p.a.) is payable to the investment management company on behalf of the fund. The expenses met by the investment management company from this fee included the expenses for portfolio management and the custodian charges (in the financial year 0.008% p.a.) as well as other third party payments (e.g. printing and publication expenses, audit fees, etc.).
Statement of Changes in Net Assets 2019
Unit class: Allianz Biotechnologie A (EUR)
- Value of the fund at beginning of financial year
	- Distribution or tax allowance for the previousEUR	EUR201,816,846.52year	-803,171.18

- Interim distributions	0.00
- Inflows (net)	30,284,071.53
	- Subscriptions	107,824,057.88of which from unit certificate sales	107,824,057.88 of which from merger		0.00

- Redemptions	-77,539,986.35
- Income equalisation/Expense equalisation	-562,552.40
- Result for the financial year	65,252,263.91of which net change in unrealised gains	27,796,516.50of which net change in unrealised losses	28,003,838.63
- Value of the fund at end of financial year	295,987,458.38Unit class: Allianz Biotechnologie R (EUR)
- Value of the fund at beginning of financial year
	- Distribution or tax allowance for the previousEUR	EUR1,680.86year	-7.45

- Interim distributions	0.00
- Inflows (net)	74,092.48
	- Subscriptions	79,176.46of which from unit certificate sales	79,176.46 of which from merger		0.00

- Redemptions	-5,083.98
- Income equalisation/Expense equalisation	-2,118.87
- Result for the financial year	3,380.53of which net change in unrealised gains	-89.48of which net change in unrealised losses	432.19
- Value of the fund at end of financial year	77,027.55Allocation of the fund’s incomeUnit class: Allianz Biotechnologie A (EUR)Calculation of distribution	total EUR	per unit EUR*)
- Available for distribution
	- Balance carried forward from previous year	33,422,149.46	19.75
	- Realised result for the financial year	9,451,908.78	5.59

- Transfers from the fund	0.00	0.00
- Not used for distribution
	- Retained for reinvestment	0.00	0.00

- Balance carried forward	-42,728,515.48	-25.25
- Gross distribution	145,542.76	0.09
	- Interim distribution	0.00	0.00

- Final distribution	145,542.76	0.09Units in circulation as at 31/12/2019: Units 1,692,358*) Unit values may be subject to rounding differences.

Unit class: Allianz Biotechnologie R (EUR)
| Calculation of distribution | total EUR | per unit EUR *) |
| --- | --- | --- |
| I. Available for distribution |  |  |
| 1. Balance carried forward from previous year | 4,659.10 | 7.61 |
| 2. Realised result for the financial year | 3,037.82 | 4.96 |
| 3. Transfers from the fund | 0.00 | 0.00 |
| II. Not used for distribution |  |  |
| 1. Retained for reinvestment | 0.00 | 0.00 |
| 2. Balance carried forward | -7,658.95 | -12.50 |
| III. Gross distribution | 37.97 | 0.06 |
| 1. Interim distribution | 0.00 | 0.00 |
| 2. Final distribution | 37.97 | 0.06 |
| Units in circulation as at 31/12/2019: Units 612 *) Unit values may be subject to rounding differences. |  |  |

Translation (ENDE, 2019-12-31):
# Allianz Biotechnologie
| Vermögensübersicht zum 31.12.2019 |  |
| --- | --- |
| Gliederung nach Anlagenart - Land | Kurswert in EUR | % des Fonds- vermögens  *) |  | Gliederung nach Anlagenart - Währung | Kurswert in EUR | % des Fonds- vermögens  *) |
| I. Vermögensgegenstände |  |  |  | I. Vermögensgegenstände |  |  |
| 1. Aktien | 266.674.855,79 | 90,09 |  | 1. Aktien | 266.674.855,79 | 90,09 |
| Niederlande | 5.799.414,37 | 1,96 |  | JPY | 2.252.980,80 | 0,76 |
| Irland | 10.491.227,17 | 3,54 |  | USD | 264.421.874,99 | 89,33 |
| Dänemark | 3.230.629,75 | 1,09 |  | 2. Derivate | 339.642,13 | 0,11 |
| Schweiz | 705.702,41 | 0,24 |  | 3. Bankguthaben, Geldmarktpapiere, | 1.978.916,80 | 0,67 |
| Großbritannien | 16.220.616,35 | 5,48 |  | Geldmarkt- und geldmarktnahe Fonds |  |  |
| USA | 223.568.226,35 | 75,53 |  | 4. Sonstige Vermögensgegenstände | 28.588.048,98 | 9,64 |

| Kanada | 3.057.704,28 | 1,03 |
| --- | --- | --- |
| Kaiman-Inseln | 944.981,11 | 0,32 |
| Britische Jungfern-Inseln | 237.951,73 | 0,08 |
| Singapur | 165.421,47 | 0,06 |
| Japan | 2.252.980,80 | 0,76 |
| 2. Derivate | 339.642,13 | 0,11 |
| 3. Bankguthaben, Geldmarktpapiere, Geldmarkt- und geldmarktnahe Fonds | 1.978.916,80 | 0,67 |
| 4. Sonstige Vermögensgegenstände | 28.588.048,98 | 9,64 |
| II. Verbindlichkeiten | -1.516.977,77 | -0,51 |
| III. Fondsvermögen | 296.064.485,93 | 100,00 |

*) 
Durch Rundung der Prozentanteile bei der Berechnung können geringfügige Run- dungsdifferenzen entstanden sein.
II. Verbindlichkeiten	-1.516.977,77	-0,51
III. Fondsvermögen	296.064.485,93	100,00
Vermögensaufstellung zum 31.12.2019
| ISIN | Gattungsbezeichnung | Markt | Stück bzw. | Bestand | Käufe/	Verkäufe/ | Kurs | Kurswert | % des |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | Anteile bzw. | 31.12.2019 | Zugänge	Abgänge |  | in EUR | Fondsver- |
| Währung	im Berichtszeitraum	mögens Börsengehandelte Wertpapiere	266.674.855,79	90,09 |
| Aktien |  |  |  |  |  |  | 266.674.855,79 | 90,09 |
| KYG596651029 | MeiraGTx Holdings PLC Reg.Shares | STK | 28.615 | 28.615 | 0 USD | 20,120 | 514.208,73 | 0,17 |
| US68570P1012 | Orchard Therapeutics PLC Reg.Shs (Sp.ADRs) | STK | 22.625 | 22.625 | 0 USD | 14,600 | 295.025,23 | 0,10 |
| US88322Q1085 | TG Therapeutics Inc. Reg.Shares | STK | 43.910 | 43.910 | 0 USD | 10,880 | 426.687,63 | 0,14 |
| Biotechnologie |  |  |  |  |  |  | 207.560.442,67 | 70,12 |
| US0042251084 | Acadia Pharmaceuticals Inc. Reg.Shares | STK | 134.640 | 101.430 | 4.080 USD | 43,970 | 5.287.474,48 | 1,79 |
| US00434H1086 | Acceleron Pharma Inc. Reg.Shares | STK | 21.495 | 21.495 | 0 USD | 51,130 | 981.591,88 | 0,33 |
| US00773U1088 | Adverum Biotechnologies Inc. Reg.Shares | STK | 150.160 | 150.160 | 0 USD | 11,210 | 1.503.410,53 | 0,51 |
| US00847X1046 | Agios Pharmaceuticals Inc. Reg.Shares | STK | 46.740 | 50.645 | 36.045 USD | 48,480 | 2.023.806,73 | 0,68 |
| US00972D1054 | Akebia Therapeutics Inc. Reg.Shares | STK | 39.220 | 39.220 | 0 USD | 6,520 | 228.387,80 | 0,08 |
| US0144421072 | Alector Inc. Reg.Shares | STK | 29.355 | 29.355 | 0 USD | 17,600 | 461.437,06 | 0,16 |
| US0153511094 | Alexion Pharmaceuticals Inc. Reg.Shares | STK | 91.600 | 55.730 | 44.480 USD | 108,550 | 8.880.614,48 | 3,00 |
| US01671P1003 | Allakos Inc. Reg.Shares | STK | 8.945 | 20.810 | 11.865 USD | 97,690 | 780.455,54 | 0,26 |
| US02043Q1076 | Alnylam Pharmaceuticals Inc Reg.Shares | STK | 40.060 | 15.800 | 67.645 USD | 117,540 | 4.205.468,14 | 1,42 |
| US0231112063 | Amarin Corp. PLC Reg.Shs (Sp.ADRs) | STK | 127.283 | 92.710 | 76.860 USD | 21,550 | 2.449.826,87 | 0,83 |
| US0311621009 | Amgen Inc. Reg.Shares | STK | 112.605 | 49.470 | 57.405 USD | 241,530 | 24.291.060,29 | 8,20 |
| US03152W1099 | Amicus Therapeutics Inc. Reg.Shares | STK | 42.055 | 42.055 | 0 USD | 9,740 | 365.842,63 | 0,12 |
| US0327241065 | Anaptysbio Inc. Reg.Shares | STK | 9.685 | 12.090 | 10.350 USD | 16,760 | 144.974,41 | 0,05 |
| US03753U1060 | Apellis Pharmaceuticals Inc. Reg.Shares | STK | 19.235 | 24.405 | 5.170 USD | 28,740 | 493.738,13 | 0,17 |
| US0400476075 | Arena Pharmaceuticals Inc. Reg.Shares New | STK | 55.985 | 30.790 | 5.730 USD | 46,050 | 2.302.602,82 | 0,78 |
| US04016X1019 | argenx SE Reg.Shares (Sp.ADRs) | STK | 15.690 | 12.820 | 4.185 USD | 160,800 | 2.253.339,88 | 0,76 |
| US04280A1007 | Arrowhead Pharmaceuticals Inc. Reg.Shares | STK | 22.745 | 27.495 | 4.750 USD | 64,930 | 1.319.012,95 | 0,45 |
| US04351P1012 | Ascendis Pharma A/S Nav.-Akt. (Spons.ADRs) | STK | 26.780 | 19.055 | 17.095 USD | 135,070 | 3.230.629,75 | 1,09 |
| US0453961080 | Assembly Biosciences Inc. Reg.Shares | STK | 45.005 | 45.005 | 0 USD | 20,935 | 841.494,82 | 0,28 |
| CA05156V1022 | Aurinia Pharmaceuticals Inc. Reg.Shares | STK | 159.830 | 159.830 | 0 USD | 21,420 | 3.057.704,28 | 1,03 |
| US07725L1026 | BeiGene Ltd. Reg.Shares (Sp.ADRs) | STK | 2.885 | 13.570 | 46.510 USD | 167,180 | 430.772,38 | 0,15 |
| US09062X1037 | Biogen Inc. Reg.Shares | STK | 58.625 | 37.155 | 48.390 USD | 300,090 | 15.712.746,17 | 5,31 |
| VGG111961055 | Biohaven Pharmac.Hldg Co.Ltd. Reg.Shares | STK | 4.755 | 9.525 | 4.770 USD | 56,030 | 237.951,73 | 0,08 |
| US09061G1013 | Biomarin Pharmaceutical Inc. Reg.Shares | STK | 92.735 | 19.695 | 48.920 USD | 85,590 | 7.088.990,89 | 2,39 |
| US09609G1004 | Bluebird Bio Inc. Reg.Shares | STK | 11.155 | 21.005 | 46.760 USD | 88,400 | 880.723,44 | 0,30 |
| US09627Y1091 | Blueprint Medicines Corp. Reg.Shares | STK | 17.715 | 7.785 | 6.460 USD | 81,270 | 1.285.846,51 | 0,43 |
| US10806X1028 | BridgeBio Pharma Inc. Reg.Shares | STK | 60.750 | 60.750 | 0 USD | 36,840 | 1.998.865,72 | 0,68 |
| US16383L1061 | ChemoCentryx Inc. Reg.Shares | STK | 60.780 | 60.780 | 0 USD | 36,230 | 1.966.739,07 | 0,66 |
| CH0334081137 | CRISPR Therapeutics AG Nam.-Aktien | STK | 11.970 | 13.345 | 34.445 USD | 66,010 | 705.702,41 | 0,24 |
| US23284F1057 | Cytomx Therapeutics Inc. Reg.Shares | STK | 36.745 | 84.040 | 164.760 USD | 8,540 | 280.268,21 | 0,09 |
| US24344T1016 | Deciphera Pharmaceuticals Inc. Reg.Shares | STK | 34.310 | 44.600 | 10.290 USD | 64,490 | 1.976.199,62 | 0,67 |
| US24823R1059 | Denali Therapeutics Inc. Reg.Shares | STK | 18.120 | 9.605 | 55.430 USD | 18,280 | 295.836,73 | 0,10 |
| US2530311081 | Dicerna Pharmaceuticals Inc. Reg.Shares | STK | 67.735 | 140.100 | 72.365 USD | 22,260 | 1.346.653,95 | 0,45 |
| US28249H1041 | Eidos Therapeutics Inc. Reg.Shares | STK | 13.560 | 54.145 | 40.585 USD | 58,610 | 709.821,46 | 0,24 |
| US29428V1044 | Epizyme Inc. Reg.Shares | STK | 90.370 | 90.370 | 0 USD | 22,620 | 1.825.721,79 | 0,62 |
| US29664W1053 | Esperion Therapeutic.Inc.(New) Reg.Shares | STK | 24.850 | 33.145 | 36.230 USD | 59,560 | 1.321.900,59 | 0,45 |
| US30063P1057 | Exact Sciences Corp. Reg.Shares | STK | 20.840 | 24.580 | 20.395 USD | 94,100 | 1.751.479,48 | 0,59 |
| US30161Q1040 | Exelixis Inc. Reg.Shares | STK | 37.530 | 45.855 | 76.835 USD | 18,130 | 607.706,78 | 0,21 |
| US31572Q8087 | FibroGen Inc. Reg.Shares | STK | 16.745 | 38.925 | 31.990 USD | 44,890 | 671.355,38 | 0,23 |
| US34983P1049 | Forty Seven Inc. Reg.Shares | STK | 74.360 | 74.360 | 0 USD | 44,050 | 2.925.519,58 | 0,99 |
| US3621LQ1099 | G1 Therapeutics Inc. Reg.Shares | STK | 13.835 | 14.640 | 13.555 USD | 27,570 | 340.669,81 | 0,12 |
| US3755581036 | Gilead Sciences Inc. Reg.Shares | STK | 304.320 | 148.605 | 171.985 USD | 65,950 | 17.925.158,75 | 6,05 |
| US37890U1088 | Global Blood Therapeutics Inc. Reg.Shares | STK | 15.510 | 27.535 | 30.470 USD | 79,150 | 1.096.428,79 | 0,37 |
| US40637H1095 | Halozyme Therapeutics Inc. Reg.Shares | STK | 105.030 | 196.565 | 91.535 USD | 17,980 | 1.686.633,68 | 0,57 |
| US4277461020 | Heron Therapeutics Inc. Reg.Shares | STK | 29.665 | 22.330 | 156.950 USD | 24,100 | 638.526,77 | 0,22 |
| US4380831077 | Homology Medicines Inc. Reg.Shares | STK | 36.290 | 36.290 | 0 USD | 21,590 | 699.773,23 | 0,24 |
| US4529071080 | Immunomedics Inc. Reg.Shares | STK | 70.245 | 31.950 | 41.555 USD | 21,770 | 1.365.814,00 | 0,46 |
| US45337C1027 | Incyte Corp. Reg.Shares | STK | 63.515 | 38.400 | 73.965 USD | 88,390 | 5.014.148,04 | 1,69 |
| US4576693075 | Insmed Inc. Reg.Shares | STK | 36.040 | 81.280 | 137.015 USD | 23,740 | 764.158,09 | 0,26 |
| US45845P1084 | Intercept Pharmaceuticals Inc. Reg.Shares | STK | 11.295 | 11.080 | 4.785 USD | 123,070 | 1.241.526,95 | 0,42 |
| US4622601007 | Iovance Biotherapeutics Inc. Reg.Shares | STK | 121.685 | 155.785 | 237.260 USD | 27,820 | 3.023.513,33 | 1,02 |
| US48576U1060 | Karyopharm Therapeutics Inc. Reg.Shares | STK | 24.040 | 37.445 | 13.405 USD | 19,250 | 413.316,66 | 0,14 |
| US4945771099 | Kindred Biosciences Inc. Reg.Shares | STK | 51.310 | 94.780 | 43.470 USD | 8,450 | 387.236,64 | 0,13 |
| US5011471027 | Krystal Biotech Inc. Reg.Shares | STK | 9.880 | 34.725 | 24.845 USD | 60,150 | 530.774,80 | 0,18 |
| US60468T1051 | Mirati Therapeutics Inc. Reg.Shares | STK | 29.355 | 53.060 | 23.705 USD | 128,430 | 3.367.179,61 | 1,14 |
| US60877T1007 | Momenta Pharmaceuticals Inc. Reg.Shares | STK | 105.570 | 105.570 | 0 USD | 20,360 | 1.919.711,70 | 0,65 |
| US6323071042 | Natera Inc. Reg.Shares | STK | 13.725 | 13.725 | 0 USD | 33,650 | 412.491,63 | 0,14 |
| US64125C1099 | Neurocrine Biosciences Inc. Reg.Shares | STK | 36.790 | 18.045 | 52.430 USD | 108,440 | 3.563.173,85 | 1,20 |
| US74257L1089 | Principia Biopharma Inc. Reg.Conv.Shares | STK | 24.725 | 24.725 | 0 USD | 59,700 | 1.318.342,79 | 0,45 |
| NL0010872495 | ProQR Therapeutics N.V. Aandelen op naam | STK | 91.070 | 68.080 | 2.820 USD | 9,410 | 765.389,81 | 0,26 |

Vermögensaufstellung zum 31.12.2019
| ISIN | Gattungsbezeichnung	Markt | Stück bzw. Anteile bzw. Währung | Bestand 31.12.2019 | Käufe/	Verkäufe/ Zugänge	Abgänge im Berichtszeitraum | Kurs | Kurswert in EUR | % des Fondsver- mögens |
| --- | --- | --- | --- | --- | --- | --- | --- |
| US74366E1029 | Protagonist Therapeutics Inc. Reg.Shares | STK | 54.350 | 91.295 | 36.945 USD | 7,000 | 339.793,69 | 0,11 |
| US69366J2006 | PTC Therapeutics Inc. Reg.Shares | STK | 53.025 | 37.310 | 3.585 USD | 48,810 | 2.311.570,80 | 0,78 |
| US75886F1075 | Regeneron Pharmaceuticals Inc. Reg.Shares | STK | 26.365 | 19.900 | 21.025 USD | 373,320 | 8.790.766,58 | 2,97 |
| US75901B1070 | Regenxbio Inc. Reg.Shares | STK | 14.555 | 21.515 | 18.885 USD | 40,540 | 527.003,71 | 0,18 |
| US77313F1066 | Rocket Pharmaceuticals Inc. Reg.Shares | STK | 19.610 | 75.155 | 55.545 USD | 24,060 | 421.396,51 | 0,14 |
| US78667J1088 | Sage Therapeutics Inc. Reg.Shares | STK | 12.825 | 27.030 | 31.140 USD | 73,350 | 840.185,55 | 0,28 |
| US8006771062 | Sangamo Therapeutics Inc. Reg.Shares | STK | 112.980 | 66.540 | 76.435 USD | 8,360 | 843.578,62 | 0,28 |
| US8036071004 | Sarepta Therapeutics Inc. Reg.Shares | STK | 34.135 | 16.680 | 21.855 USD | 129,770 | 3.956.324,70 | 1,34 |
| US8125781026 | Seattle Genetics Inc. Reg.Shares | STK | 65.610 | 51.530 | 41.980 USD | 113,420 | 6.646.261,06 | 2,24 |
| US90041T1088 | Turning Point Therap. Inc. Reg.Shares | STK | 41.440 | 50.695 | 9.255 USD | 60,630 | 2.244.011,25 | 0,76 |
| NL0010696654 | uniQure N.V. Aandelen op naam | STK | 39.780 | 42.635 | 2.855 USD | 72,500 | 2.575.849,60 | 0,87 |
| US92532F1003 | Vertex Pharmaceuticals Inc. Reg.Shares | STK | 113.835 | 48.735 | 24.180 USD | 220,970 | 22.466.056,31 | 7,59 |
| Biowissenschaften Hilfsmittel & Dienstleistungen |  |  |  |  |  | 12.662.129,10 | 4,28 |
| US4523271090	Illumina Inc. Reg.Shares | STK | 42.665 | 38.255 | 48.710 USD | 332,290 | 12.662.129,10 | 4,28 |
| Gesundheitswesen: Ausstattung & Produkte |  |  |  |  |  | 7.698.497,14 | 2,60 |
| US08862L1035	Beyond Air Inc. Reg.Shares | STK | 394.056 | 394.056 | 0 USD | 4,380 | 1.541.522,15 | 0,52 |
| JE00BYSS4X48	Novocure Ltd. Reg.Shares | STK | 58.705 | 14.585 | 32.830 USD | 87,560 | 4.590.907,69 | 1,55 |
| JE00BLG2ZQ72	Quotient Ltd. Reg.Shares | STK | 192.475 | 43.065 | 121.645 USD | 9,110 | 1.566.067,30 | 0,53 |
| Gesundheitswesen: Einrichtungen & Dienste |  |  |  |  |  | 1.004.437,73 | 0,34 |
| US40131M1099	Guardant Health Inc. Reg.Shares Cl.A | STK | 14.270 | 14.270 | 0 USD | 78,810 | 1.004.437,73 | 0,34 |
| Pharmazeutika |  |  |  |  |  | 36.513.427,56 | 12,34 |
| US00771V1089	Aerie Pharmaceuticals Inc. Reg.Shares | STK | 30.430 | 5.060 | 3.110 USD | 24,020 | 652.818,83 | 0,22 |
| US0463531089	Astrazeneca PLC Reg.Shares (Spons.ADRs)	STK | 162.460 | 177.205 | 106.995 USD | 50,440 | 7.318.789,26 | 2,47 |
| US1101221083	Bristol-Myers Squibb Co. Reg.Shares | STK | 140.870 | 207.715 | 66.845 USD | 64,140 | 8.069.844,86 | 2,73 |
| JP3475350009	Daiichi Sankyo Co. Ltd. Reg.Shares | STK | 38.100 | 38.100 | 0 JPY | 7.228,000 | 2.252.980,80 | 0,76 |
| US24983L1044	Dermira Inc. Reg.Shares | STK | 172.745 | 236.070 | 63.325 USD | 14,550 | 2.244.844,15 | 0,76 |
| IE00BQPVQZ61	Horizon Therapeutics PLC Reg.Shares | STK | 323.150 | 420.100 | 96.950 USD | 36,350 | 10.491.227,17 | 3,54 |
| US46116X1019	Intra-Cellular Therapies Inc. Reg.Shares | STK | 21.835 | 49.880 | 28.045 USD | 35,225 | 686.944,92 | 0,23 |
| NL0011031208	Mylan N.V. Aandelen aan toonder | STK | 11.630 | 246.960 | 447.445 USD | 19,720 | 204.835,08 | 0,07 |
| US62857M1053	Myokardia Inc. Reg.Shares | STK | 6.105 | 15.415 | 32.715 USD | 74,120 | 404.146,47 | 0,14 |
| US6402681083	Nektar Therapeutics Reg.Shares | STK | 38.555 | 40.710 | 19.895 USD | 21,570 | 742.760,10 | 0,25 |
| US6760791060	Odonate Therapeutics Inc. Reg.Shares | STK | 23.430 | 1.230 | 85.400 USD | 29,520 | 617.740,90 | 0,21 |
| US75615P1030	Reata Pharmaceuticals Inc. Reg.Shares | STK | 14.100 | 14.100 | 0 USD | 211,310 | 2.661.073,55 | 0,90 |
| SG9999014716	Wave Life Sciences Ltd. Reg.Shares | STK | 11.715 | 3.865 | 18.920 USD | 15,810 | 165.421,47 | 0,06 |
| Summe Wertpapiervermögen |  |  |  | EUR |  | 266.674.855,79 | 90,09 |
| Derivate |  |  |  |  |  |  |  |
| (Bei den mit Minus gekennzeichneten Beständen handelt es sich um verkaufte Positionen) |
| Derivate auf einzelne Wertpapiere |  |  |  |  |  |  |  |  |
| Optionsscheine |  |  |  |  |  |  | 339.642,13 | 0,11 |
| Optionsscheine auf Aktien |  |  |  |  |  |  | 339.642,13 | 0,11 |
| Advanced Inhalation WTS |  |  |  |  |  |  |  |  |
| (Foreign) 16/29.12.21 Advanced Inhalation WTS | X | STK | 333.334 | 0 | 0 USD | 0,739 | 220.009,67 | 0,07 |
| (Foreign) 18/01.02.21 OncoGenex Pharmac. WTS | X | STK | 227.389 | 0 | 0 USD | 0,589 | 119.619,63 | 0,04 |
| (Foreign) 04/02.07.19 | A | STK | 143.678 | 0 | 0 USD | 0,0001 | 12,83 | 0,00 |
| Summe Derivate auf einzelne Wertpapiere |  |  | EUR |  | 339.642,13 | 0,11 |
| Bankguthaben, Geldmarktpapiere, Geldmarkt- und geldmarktnahe Fonds |  |  |  |  |  |  |
| Guthaben in Nicht-EU/EWR-Währungen |  |  |  |  |  |  |
| State Street Bank International GmbH | USD | 2.215.694,20 | % | 100,000 | 1.978.916,80 | 0,67 |
| Summe Bankguthaben |  | EUR | 1.978.916,80 | 0,67 |
| Summe der Bankguthaben, Geldmarktpapiere, Geldmarkt- und geldmarktnahe Fonds |  | EUR | 1.978.916,80 | 0,67 |
| Sonstige Vermögensgegenstände |  |  |  |  |
| Forderungen aus Anteilscheingeschäften	EUR | 27.368.330,76 |  | 27.368.330,76 | 9,23 |
| Forderungen aus Wertpapiergeschäften	EUR | 1.219.718,22 |  | 1.219.718,22 | 0,41 |
| Summe Sonstige Vermögensgegenstände |  | EUR | 28.588.048,98 | 9,64 |
| Kurzfristige Verbindlichkeiten |  |  |  |  |
| EUR-Kredite bei der Verwahrstelle |  |  |  |  |
| State Street Bank International GmbH	EUR | -243.774,22 |  | -243.774,22 | -0,08 |
| Summe Kurzfristige Verbindlichkeiten |  | EUR | -243.774,22 | -0,08 |
| Sonstige Verbindlichkeiten |  |  |  |  |
| Verbindlichkeiten aus Anteilscheingeschäften	EUR | -271.440,42 |  | -271.440,42 | -0,09 |
| Verbindlichkeiten aus Wertpapiergeschäften	EUR | -540.587,45 |  | -540.587,45 | -0,18 |

Vermögensaufstellung zum 31.12.2019
| ISIN | Gattungsbezeichnung	Markt	Stück bzw. | Bestand | Käufe/	Verkäufe/ |  | Kurs | Kurswert | % des |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | Anteile bzw. Währung | 31.12.2019 | Zugänge	Abgänge im Berichtszeitraum |  |  | in EUR | Fondsver- mögens |
|  | Kostenabgrenzung	EUR | -461.175,68 |  |  |  | -461.175,68 | -0,16 |
| Summe Sonstige | Verbindlichkeiten |  |  | EUR |  | -1.273.203,55 | -0,43 |
| Fondsvermögen |  |  |  | EUR |  | 296.064.485,93 | 100,00 |
|  | Summe der umlaufenden Anteile aller Anteilklassen |  |  | STK |  | 1.692.970 |  |

Allianz Biotechnologie A (EUR)
| ISIN | DE0008481862 |
| --- | --- |
| Fondsvermögen | 295.987.458,38 |
| Umlaufende Anteile | 1.692.357,701 |
| Anteilwert | 174,90 |

Allianz Biotechnologie R (EUR)
| ISIN | DE000A2AMPU5 |
| --- | --- |
| Fondsvermögen | 77.027,55 |
| Umlaufende Anteile | 612,480 |
| Anteilwert | 125,76 |

Wertpapierkurse bzw. Marktsätze
Die Vermögensgegenstände des Sondervermögens sind auf der Grundlage nachstehender Kurse/Marktsätze bewertet: Aktien Nord- und Südamerika: Kurse per 27.12.2019 oder letztbekannte
Alle anderen Vermögenswerte: Kurse bzw. Marktsätze per 30.12.2019 oder letztbekannte
Devisenkurs(e) bzw. Konversionsfaktor(en) (in Mengennotiz) per 30.12.2019
| USA, Dollar | (USD) | 1 Euro = USD | 1,11965 |
| --- | --- | --- | --- |
| Japan, Yen | (JPY) | 1 Euro = JPY | 122,23220 |
| Marktschlüssel |  |  |  |
| Wertpapierhandel |  |  |  |
| A | = | Amtlicher Börsenhandel |
| X | = | Nichtnotierte Wertpapiere |
| Kapitalmaßnahmen |  |  |

Alle Umsätze, die aus Kapitalmaßnahmen hervorgehen (technische Umsätze), werden als Zu- oder Abgang ausgewiesen.
Stimmrechtsausübung
Stimmrechte aus den im Fonds enthaltenen Aktien haben wir, soweit es im Interesse unserer Anleger geboten erschien, entweder selbst wahrgenommen oder durch Beauftragte nach unseren Weisungen ausüben lassen.
Während des Berichtszeitraumes abgeschlossene Geschäfte, soweit sie nicht mehr in der Vermögensaufstellung erscheinen: Käufe und Verkäufe in Wertpapieren, Investmentanteilen und Schuldscheindarlehen (Marktzuordnung zum Berichtsstichtag):
| ISIN | Gattungsbezeichnung | Stück bzw. | Käufe/ | Verkäufe/ |
| --- | --- | --- | --- | --- |
|  |  | Anteile bzw. Währung | Zugänge | Abgänge |

Börsengehandelte Wertpapiere Aktien
Biotechnologie
| US00287Y1091 | AbbVie Inc. Reg.Shares | STK | 26.660 | 26.660 |
| --- | --- | --- | --- | --- |
| IE00B56GVS15 | Alkermes PLC Reg.Shares | STK | 0 | 28.085 |
| US04269E1073 | ArQule Inc. Reg.Shares | STK | 173.345 | 173.345 |
| US05070R1041 | Audentes Therapeutics Inc. Reg.Shares | STK | 2.885 | 19.145 |
| US05280R1005 | Autolus Therapeutics Ltd. Reg.Shs (Spons. ADRs) | STK | 17.295 | 32.105 |
| US09058V1035 | BioCryst Pharmaceuticals Inc. Reg.Shares | STK | 46.480 | 46.480 |
| US1510201049 | Celgene Corp. Reg.Shares | STK | 76.690 | 254.960 |
| US1894641000 | Clovis Oncology Inc. Reg.Shares | STK | 23.550 | 23.550 |
| US28106W1036 | Editas Medicine Inc. Reg.Shares | STK | 7.085 | 49.780 |
| US38000Q1022 | GlycoMimetics Inc. Reg.Shares | STK | 76.965 | 76.965 |
| US45253H1014 | ImmunoGen Inc. Reg.Shares | STK | 61.655 | 61.655 |
| US45826J1051 | Intellia Therapeutics Inc. Reg.Shares | STK | 1.990 | 18.365 |
| US46185L1035 | Invitae Corp. Reg.Shares | STK | 27.850 | 154.125 |
| US4622221004 | Ionis Pharmaceuticals Inc. Reg.Shares | STK | 2.920 | 38.800 |
| US5560991094 | MacroGenics Inc. Reg.Shares | STK | 28.000 | 28.000 |
| US62855J1043 | Myriad Genetics Inc. Reg.Shares | STK | 27.705 | 27.705 |
| US7370101088 | Portola Pharmaceuticals Inc. Reg.Shares | STK | 26.915 | 26.915 |
| US74373B1098 | Proteostasis Therapeutics Inc. Reg.Shares | STK | 7.220 | 66.645 |
| US7504692077 | Radius Health Inc. Reg.Shares | STK | 5.715 | 52.770 |
| US7612991064 | Retrophin Inc. Reg.Shares | STK | 29.810 | 45.350 |
| US84763A1088 | Spectrum Pharmaceuticals Inc. Reg.Shares New | STK | 44.385 | 44.385 |
| US5846881051 | The Medicines Co. Reg.Shares | STK | 86.965 | 113.335 |
| US90400D1081 | Ultragenyx Pharmaceutical Inc. Reg.Shares | STK | 2.145 | 19.800 |
| US91307C1027 | United Therapeutics Corp.(Del.) Reg.Shares | STK | 5.655 | 5.655 |
| Biowissenschaften Hilfsmittel & Dienstleistungen |
| US00650F1093 | Adaptive Biotechnologies Corp. Reg.Shares | STK | 50.000 | 50.000 |
| US09073M1045 | Bio-Techne Corp. Reg.Shares | STK | 1.670 | 15.443 |
| US63009R1095 | NanoString Technologies Inc. Reg.Shares | STK | 14.000 | 14.000 |
| US69354M1080 | PRA Health Sciences Inc. Reg.Shares | STK | 3.035 | 28.035 |
| US87166B1026 | Syneos Health Inc. Reg.Shares A | STK | 17.615 | 17.615 |
| Gesundheitswesen: Ausstattung & Produkte |
| US0014481099 | AIT Therapeutics Inc. Reg.Shares | STK | 0 | 394.056 |
| Pharmazeutika |  |  |  |  |
| US1407551092 | Cara Therapeutics Inc. Reg.Shares | STK | 30.870 | 44.730 |
| US23257D1037 | CymaBay Therapeutics Inc. Reg.Shares | STK | 24.000 | 24.000 |
| US28414H1032 | Elanco Animal Health Inc. Reg.Shares | STK | 9.494,691 | 9.494,691 |
| US36197T1034 | GW Pharmaceuticals PLC Reg.Shs (Sp.ADRs) | STK | 690 | 6.380 |

An organisierten Märkten zugelassene oder in diese einbezogene Wertpapiere Aktien
Biotechnologie
US04269X1054	Array Biopharma Inc. Reg.Shares	STK	9.375	86.530
US84652J1034	Spark Therapeutics Inc. Reg.Shares	STK	18.930	48.030
Pharmazeutika
US03874P1012	Aratana Therapeutics Inc. Reg.Shares	STK	70.000	70.000
Nichtnotierte Wertpapiere Aktien
Biotechnologie
US0143391052	Alder BioPharmaceuticals Inc. Reg.Shares	STK	3.450	31.860
Derivate
Gattungsbezeichnung	Stück bzw.	Volumen
Anteile bzw.	in 1.000
Währung
(In Opening-Transaktionen umgesetzte Optionsprämien bzw. Volumen der Optionsgeschäfte, bei Optionsscheinen Angabe der Käufe und Verkäufe.)
Devisentermingeschäfte Devisenterminkontrakte (Kauf) Verkauf von Devisen auf Termin:
USD/EUR	EUR	577
| Ertrags- und Aufwandsrechnung Anteilklasse: Allianz Biotechnologie A | (EUR) |  |  | Anteilklasse: Allianz Biotechnologie R | (EUR) |  |
| --- | --- | --- | --- | --- | --- | --- |
| für den Zeitraum vom 01.01.2019 - 31.12.2019 |  |  |  | für den Zeitraum vom 01.01.2019 - 31.12.2019 |  |
| (einschließlich Ertragsausgleich) |  |  |  | (einschließlich Ertragsausgleich) |  |
|  | EUR | EUR |  |  | EUR | EUR |
| I. Erträge |  |  |  | I. Erträge |  |  |
| 1. Dividenden inländischer Aussteller (vor |  |  |  | 1. Dividenden inländischer Aussteller (vor |  |  |
| Körperschaftsteuer) |  | 0,00 |  | Körperschaftsteuer) |  | 0,00 |
| 2. Dividenden ausländischer Aussteller (vor |  |  |  | 2. Dividenden ausländischer Aussteller (vor |  |  |
| Quellensteuer) |  | 1.789.128,49 |  | Quellensteuer) |  | 462,70 |
| 3. Zinsen aus inländischen Wertpapieren |  | 0,00 |  | 3. Zinsen aus inländischen Wertpapieren |  | 0,00 |
| 4. Zinsen aus ausländischen Wertpapieren (vor |  |  |  | 4. Zinsen aus ausländischen Wertpapieren (vor |  |  |
| Quellensteuer) |  | 0,00 |  | Quellensteuer) |  | 0,00 |
| 5. Zinsen aus Liquiditätsanlagen im Inland |  | -12.870,37 |  | 5. Zinsen aus Liquiditätsanlagen im Inland |  | -2,94 |
| a) Negative Einlagezinsen | -13.476,18 |  |  | a) Negative Einlagezinsen | -2,94 |  |
| b) Positive Einlagezinsen | 605,81 |  |  | 6. Zinsen aus Liquiditätsanlagen im Ausland (vor |  |  |
| 6. Zinsen aus Liquiditätsanlagen im Ausland (vor |  |  |  | Quellensteuer) |  | 0,00 |
| Quellensteuer) |  | 0,00 |  | 7. Erträge aus Investmentanteilen |  | 0,00 |
| 7. Erträge aus Investmentanteilen |  | 0,00 |  | 8. Erträge aus Wertpapier-Darlehen- und |  |  |
| 8. Erträge aus Wertpapier-Darlehen- und |  |  |  | -Pensionsgeschäften |  | 0,00 |
| -Pensionsgeschäften |  | 0,00 |  | 9a. Abzug inländischer Körperschaftsteuer |  | 0,00 |
| 9a. Abzug inländischer Körperschaftsteuer |  | 0,00 |  | 9b. Abzug ausländischer Quellensteuer |  | -124,93 |
| 9b. Abzug ausländischer Quellensteuer |  | -477.893,64 |  | a) aus Dividenden ausländischer Aussteller | -124,93 |  |
| a) aus Dividenden ausländischer Aussteller | -477.893,64 |  |  | 10. Sonstige Erträge |  | 133,78 |
| 10. Sonstige Erträge |  | 517.264,66 |  | Summe der Erträge |  | 468,61 |
| Summe der Erträge |  | 1.815.629,14 |  | II. Aufwendungen |  |  |
| II. Aufwendungen |  |  |  | 1. Zinsen aus Kreditaufnahmen |  | -0,59 |
| 1. Zinsen aus Kreditaufnahmen |  | -5.722,90 |  | 2. Pauschalvergütung 1) |  | -795,47 |
| 2. Pauschalvergütung 1) |  | -5.334.203,15 |  | 3. Verwahrstellenvergütung |  | 0,00 |
| 3. Verwahrstellenvergütung |  | 0,00 |  | 4. Prüfungs- und Veröffentlichungskosten |  | 0,00 |
| 4. Prüfungs- und Veröffentlichungskosten |  | 0,00 |  | 5. Sonstige Aufwendungen |  | -0,44 |
| 5. Sonstige Aufwendungen |  | -4.096,83 |  | Summe der Aufwendungen |  | -796,50 |
| Summe der Aufwendungen |  | -5.344.022,88 |  | III. Ordentlicher Nettoertrag |  | -327,89 |
| III. Ordentlicher Nettoertrag IV. Veräußerungsgeschäfte |  | -3.528.393,74 |  | IV. Veräußerungsgeschäfte 1. Realisierte Gewinne |  | 9.879,41 |
| 1. Realisierte Gewinne |  | 38.121.590,72 |  | 2. Realisierte Verluste |  | -6.513,70 |
| 2. Realisierte Verluste |  | -25.141.288,20 |  | Ergebnis aus Veräußerungsgeschäften |  | 3.365,71 |
| Ergebnis aus Veräußerungsgeschäften |  | 12.980.302,52 |  | V. Realisiertes Ergebnis des Geschäftsjahres |  | 3.037,82 |
| V. Realisiertes Ergebnis des Geschäftsjahres |  | 9.451.908,78 |  | 1. Nettoveränderung der nicht realisierten |  |  |
| 1. Nettoveränderung der nicht realisierten |  |  |  | Gewinne |  | -89,48 |
| Gewinne |  | 27.796.516,50 |  | 2. Nettoveränderung der nicht realisierten |  |  |
| 2. Nettoveränderung der nicht realisierten |  |  |  | Verluste |  | 432,19 |
| Verluste |  | 28.003.838,63 |  | VI. Nicht realisiertes Ergebnis des Geschäfts- |  | 342,71 |
| VI. Nicht realisiertes Ergebnis des Geschäfts- |  | 55.800.355,13 |  | jahres |  |  |
| jahres |  |  |  | VII. Ergebnis des Geschäftsjahres |  | 3.380,53 |

VII. Ergebnis des Geschäftsjahres	65.252.263,91
1) 
Gemäß den Vertragsbedingungen ist für das Sondervermögen eine an die Kapi- talverwaltungsgesellschaft abzuführende Pauschalvergütung („All-In-Fee“) in der Höhe von 2,05 % p.a. (im Geschäftsjahr 2,05 % p.a.) vereinbart. Hieraus bestritt die Kapitalverwaltungsgesellschaft die Kosten für das Portfoliomanagement sowie un- ter anderem die Aufwendungen für die Verwahrstelle (im Geschäftsjahr 0,008 % p.a.) und für Sonstige Dritte (z.B. Druck- und Veröffentlichungskosten, Abschlussprü- fung, etc.).
1) 
Gemäß den Vertragsbedingungen ist für das Sondervermögen eine an die Kapi- talverwaltungsgesellschaft abzuführende Pauschalvergütung („All-In-Fee“) in der Höhe von 2,05 % p.a. (im Geschäftsjahr 1,18 % p.a.) vereinbart. Hieraus bestritt die Kapitalverwaltungsgesellschaft die Kosten für das Portfoliomanagement sowie un- ter anderem die Aufwendungen für die Verwahrstelle (im Geschäftsjahr 0,008 % p.a.) und für Sonstige Dritte (z.B. Druck- und Veröffentlichungskosten, Abschlussprü- fung, etc.).
Entwicklung des Sondervermögens 2019
Anteilklasse: Allianz Biotechnologie A (EUR)
|  | EUR | EUR |
| --- | --- | --- |
| I. Wert des Sondervermögens am Beginn des Geschäftsjahres |  | 201.816.846,52 |
| 1. Ausschüttung bzw. Steuerabschlag für das |  |  |
| Vorjahr |  | -803.171,18 |
| 2. Zwischenausschüttung(en) |  | 0,00 |
| 3. Mittelzufluss (netto) |  | 30.284.071,53 |
| a) Mittelzuflüsse aus Anteilschein-Verkäufen | 107.824.057,88 |  |
| davon aus Anteilschein-Verkäufen | 107.824.057,88 |  |
| davon aus Verschmelzung | 0,00 |  |
| b) Mittelabflüsse aus Anteilschein-Rücknahmen | -77.539.986,35 |  |
| 4. Ertragsausgleich/Aufwandsausgleich |  | -562.552,40 |
| 5. Ergebnis des Geschäftsjahres |  | 65.252.263,91 |
| davon Nettoveränderung der nicht realisierten |  |  |
| Gewinne | 27.796.516,50 |  |
| davon Nettoveränderung der nicht realisierten |  |  |
| Verluste | 28.003.838,63 |  |
| II. Wert des Sondervermögens am Ende des Geschäftsjahres |  | 295.987.458,38 |

Anteilklasse: Allianz Biotechnologie R (EUR)
|  | EUR | EUR |
| --- | --- | --- |
| I. Wert des Sondervermögens am Beginn des Geschäftsjahres |  | 1.680,86 |
| 1. Ausschüttung bzw. Steuerabschlag für das |  |  |
| Vorjahr |  | -7,45 |
| 2. Zwischenausschüttung(en) |  | 0,00 |
| 3. Mittelzufluss (netto) |  | 74.092,48 |
| a) Mittelzuflüsse aus Anteilschein-Verkäufen | 79.176,46 |  |
| davon aus Anteilschein-Verkäufen | 79.176,46 |  |
| davon aus Verschmelzung | 0,00 |  |
| b) Mittelabflüsse aus Anteilschein-Rücknahmen | -5.083,98 |  |
| 4. Ertragsausgleich/Aufwandsausgleich |  | -2.118,87 |
| 5. Ergebnis des Geschäftsjahres |  | 3.380,53 |
| davon Nettoveränderung der nicht realisierten |  |  |
| Gewinne | -89,48 |  |
| davon Nettoveränderung der nicht realisierten |  |  |
| Verluste | 432,19 |  |
| II. Wert des Sondervermögens am Ende des Geschäftsjahres |  | 77.027,55 |

Verwendung der Erträge des Sondervermögens
Anteilklasse: Allianz Biotechnologie A (EUR)
| Berechnung der Ausschüttung | insgesamt EUR | je Anteil EUR *) |
| --- | --- | --- |
| I. Für die Ausschüttung verfügbar |  |  |
| 1. Vortrag aus dem Vorjahr | 33.422.149,46 | 19,75 |
| 2. Realisiertes Ergebnis des Geschäftsjahres | 9.451.908,78 | 5,59 |
| 3. Zuführung aus dem Sondervermögen | 0,00 | 0,00 |
| II. Nicht für die Ausschüttung verwendet |  |  |
| 1. Der Wiederanlage zugeführt | 0,00 | 0,00 |
| 2. Vortrag auf neue Rechnung | -42.728.515,48 | -25,25 |
| III. Gesamtausschüttung | 145.542,76 | 0,09 |
| 1. Zwischenausschüttung | 0,00 | 0,00 |
| 2. Endausschüttung | 145.542,76 | 0,09 |

Umlaufende Anteile per 30.12.2019: Stück 1.692.358
*) Rundungsbedingte Differenzen bei den je Anteil-Werten sind möglich.
Anteilklasse: Allianz Biotechnologie R (EUR)
| Berechnung der Ausschüttung | insgesamt EUR | je Anteil EUR *) |
| --- | --- | --- |
| I. Für die Ausschüttung verfügbar |  |  |
| 1. Vortrag aus dem Vorjahr | 4.659,10 | 7,61 |
| 2. Realisiertes Ergebnis des Geschäftsjahres | 3.037,82 | 4,96 |
| 3. Zuführung aus dem Sondervermögen | 0,00 | 0,00 |
| II. Nicht für die Ausschüttung verwendet |  |  |
| 1. Der Wiederanlage zugeführt | 0,00 | 0,00 |
| 2. Vortrag auf neue Rechnung | -7.658,95 | -12,50 |
| III. Gesamtausschüttung | 37,97 | 0,06 |
| 1. Zwischenausschüttung | 0,00 | 0,00 |
| 2. Endausschüttung | 37,97 | 0,06 |

Umlaufende Anteile per 30.12.2019: Stück 612
*) Rundungsbedingte Differenzen bei den je Anteil-Werten sind möglich.